DK1677797T3 - Salte og polymorfer af en virkningsfuld antidiabetisk forbindelse - Google Patents

Salte og polymorfer af en virkningsfuld antidiabetisk forbindelse

Info

Publication number
DK1677797T3
DK1677797T3 DK04794053.1T DK04794053T DK1677797T3 DK 1677797 T3 DK1677797 T3 DK 1677797T3 DK 04794053 T DK04794053 T DK 04794053T DK 1677797 T3 DK1677797 T3 DK 1677797T3
Authority
DK
Denmark
Prior art keywords
polymorphs
salts
compound
antidiabetic compound
treatment
Prior art date
Application number
DK04794053.1T
Other languages
English (en)
Inventor
Henry T Kruk
Lawrence R Mcgee
Bing Yang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1677797T3 publication Critical patent/DK1677797T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK04794053.1T 2003-10-03 2004-10-04 Salte og polymorfer af en virkningsfuld antidiabetisk forbindelse DK1677797T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50847003P 2003-10-03 2003-10-03
PCT/US2004/032552 WO2005033074A2 (en) 2003-10-03 2004-10-04 Salts and polymorphs of a potent antidiabetic compound

Publications (1)

Publication Number Publication Date
DK1677797T3 true DK1677797T3 (da) 2012-06-04

Family

ID=34421741

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04794053.1T DK1677797T3 (da) 2003-10-03 2004-10-04 Salte og polymorfer af en virkningsfuld antidiabetisk forbindelse

Country Status (19)

Country Link
US (2) US7223761B2 (da)
EP (1) EP1677797B1 (da)
JP (2) JP5426813B2 (da)
KR (1) KR101156277B1 (da)
CN (1) CN1886134A (da)
AT (1) ATE546142T1 (da)
AU (1) AU2004278416B2 (da)
BR (1) BRPI0414957A (da)
CA (1) CA2540536C (da)
DK (1) DK1677797T3 (da)
EA (1) EA013367B1 (da)
ES (1) ES2386670T3 (da)
IL (1) IL174728A (da)
IS (1) IS8378A (da)
MX (1) MXPA06003313A (da)
NO (1) NO333002B1 (da)
NZ (1) NZ546783A (da)
WO (1) WO2005033074A2 (da)
ZA (1) ZA200602669B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US6653332B2 (en) 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
CN101511170B (zh) * 2005-12-22 2014-03-26 奥克伍德药业有限公司 可升华持续释放传递系统和其制造方法
US8269010B2 (en) * 2006-09-21 2012-09-18 Piramal Healthcare Limited 3-amino-pyridine derivatives for the treatment of metabolic disorders
WO2009111078A2 (en) * 2008-03-06 2009-09-11 Intekrin Therapeutics, Inc. Combination of a ppary agonist and a dipeptidyl peptidase-inhibitor for the treatment of diabetes and obesity
WO2010040055A2 (en) * 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
US20110034380A1 (en) * 2009-08-05 2011-02-10 Dennis Lanfear Combination of a selective ppar-gamma modulator and an incretin for the treatment of diabetes and obesity
MX363549B (es) * 2010-09-21 2019-03-26 Intekrin Therapeutics Inc Star Composiciones farmacéuticas sólidas antidiabéticas.
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
BR112015018048A2 (pt) * 2013-01-30 2020-01-28 Intekrin Therapeutics Inc agonistas de ppary para tratamento de esclerose múltipla
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
WO2017178408A1 (en) 2016-04-15 2017-10-19 Syngenta Participations Ag Microbiocidal silicon containing aryl derivatives
CN109843292A (zh) * 2016-08-18 2019-06-04 因特克林治疗股份有限公司 治疗骨疾病的PPARγ激动剂
CA3034258A1 (en) * 2016-08-18 2018-02-22 Intekrin Therapeutics, Inc. Ppar.gamma. agonist for treatment of blood cancers
BR112019004791A2 (pt) * 2016-09-13 2019-06-04 Intekrin Therapeutics Inc tratamento de esclerose múltipla com chs-131
CN110461330A (zh) * 2017-01-18 2019-11-15 科赫罗斯生物科学股份有限公司 用于治疗亨廷顿氏病的PPARγ激动剂
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
CN109651208B (zh) * 2017-10-10 2022-01-04 中国科学院上海药物研究所 N-芳基磺酰胺类化合物，其药物组合物及其用途
CA3125341A1 (en) 2018-12-31 2020-07-09 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2020205027A1 (en) 2019-04-02 2020-10-08 Christos Mantzoros Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
US20220288053A1 (en) 2019-04-04 2022-09-15 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
US20220175758A1 (en) 2019-04-04 2022-06-09 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
EP3946337A1 (en) 2019-04-04 2022-02-09 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
US20220288054A1 (en) 2019-04-04 2022-09-15 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2020243058A1 (en) 2019-05-30 2020-12-03 Coherus Biosciences, Inc. Compositions and methods to treat cancer
WO2021076616A1 (en) 2019-10-15 2021-04-22 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2022051319A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a dpp-4 inhibitor
WO2022051318A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a thyroid receptor beta agonist
WO2022051316A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a sglt-2 inhibitor
WO2022051323A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a ppar agonist
WO2022051321A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a fxr agonist
JP2022104747A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗ウイルス剤

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2407309A (en) 1942-02-04 1946-09-10 Squibb & Sons Inc Chemotherapeutic agents of the sulphonamide type
CH361275A (de) 1957-09-10 1962-04-15 Geigy Ag J R Verfahren zur Herstellung von neuen Arylsulfonarylamiden
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
NL138933B (nl) 1969-03-26 1973-05-15 Erba Carlo Spa Werkwijze voor het bereiden van benzeensulfonylureumderivaten met bloedsuikerspiegelverlagende werking.
US3700773A (en) 1969-06-25 1972-10-24 Merck & Co Inc Substituted phenylsulfamyl salicyclic acids and derivatives thereof in the treatment of inflammation
US3686192A (en) 1971-01-04 1972-08-22 Minnesota Mining & Mfg Substituted pyridine derivatives
US4061642A (en) 1972-06-22 1977-12-06 Cassella Farbwerke Mainkur Ag 2,4,6-Trisubstituted-3-pyridine carboxamides
US4062950A (en) 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
US4003734A (en) 1974-01-22 1977-01-18 The Dow Chemical Company Substituted pyridinyloxy(thio)phenyl-acetamides, -ureas and urea derivatives and herbicidal compositions and methods containing said compounds
CH592411A5 (en) 1974-04-18 1977-10-31 Ciba Geigy Ag Phenoxymethyl- and phenylthiomethyl-pyridine derivs - with insecticidal, acaricidal and plant-growth regulating activity
US4013621A (en) 1975-04-29 1977-03-22 Ciba-Geigy Corporation Substituted sulfonamide derivatives of hindered phenols and stabilized compositions
GB2009146B (en) 1977-11-29 1982-03-24 Ishihara Sangyo Kaisha Sulphonanilide copmouds and herbicidal compositions therof
US4289876A (en) 1978-11-24 1981-09-15 Bristol-Myers Company Antisecretory agents
JPS5579369A (en) 1978-12-13 1980-06-14 Ishihara Sangyo Kaisha Ltd Urea compound, its preparation, and insecticide comprising it
US4499304A (en) 1981-07-06 1985-02-12 Eastman Kodak Company Color-forming sulfonamidodiphenylamines and corresponding sulfonimide dyes
EP0069585B1 (en) 1981-07-06 1985-07-03 EASTMAN KODAK COMPANY (a New Jersey corporation) Color-forming sulfonamidodiphenylamines, photographic elements containing them and corresponding sulfonimide dyes
DE3280205D1 (de) 1981-10-20 1990-08-09 Ciba Geigy Ag 5-halogenalkyl-pyridine.
US4565568A (en) 1982-06-18 1986-01-21 The Dow Chemical Company Pyridyl(oxy/thio)phenoxy compounds, herbicidal compositions and methods
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4731090A (en) 1983-12-23 1988-03-15 Ciba-Geigy Corporation Process for protecting keratinous material from attack by insects feed on keratin with pyridyloxytrifluoromethanesulfonanilides
US4549901A (en) 1984-02-16 1985-10-29 Stauffer Chemical Company 2-[4-(Substituted aryl)phenoxy]-N-substituted-phenylsulfonyl propionamides having herbicidal properties
US4851419A (en) 1985-10-16 1989-07-25 Fisons Plc Certain 2-pyridinyl-phenylsulfinyl-benzoxazoles, the corresponding benzothiazoles or benzimidazoles having anti-inflammatory or gastric acid secretion inhibition activity
DE3545570A1 (de) 1985-12-21 1987-06-25 Hoechst Ag Neue pyridin-derivate und deren n-oxide, verfahren zu ihrer herstellung und ihre verwendung als zwischenprodukte
US4866079A (en) 1986-03-19 1989-09-12 Ciba-Geigy Corporation N-pyridyloxyphenylisothioureas and the use thereof in pest control
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
US5202336A (en) 1986-09-24 1993-04-13 Bayer Aktiengesellschaft Antiflammatory quinolin methoxy phenylsulphonamides
AU604771B2 (en) 1986-09-27 1991-01-03 Fisons Plc Pyridinylphenylthio and pyridinylphenylsulphinyl benzimidazone derivatives
JPS646245A (en) 1987-02-20 1989-01-10 Sumitomo Chemical Co Benzylamine derivative, production thereof and germicide containing said derivative as active ingredient
US4670045A (en) 1987-04-07 1987-06-02 The Dow Chemical Company Fungicidal control employing ester derivatives of 4,6-disubstituted 2-pyridinols
GB8724252D0 (en) 1987-10-15 1987-11-18 Ici Plc Fungicides
JPS646245U (da) 1987-06-30 1989-01-13
JPH01156953A (ja) 1987-09-01 1989-06-20 Hokko Chem Ind Co Ltd ベンゼンスルホンアニリド誘導体および農園芸用殺菌剤
DE3852621D1 (de) 1987-12-07 1995-02-09 Ciba Geigy Ag 3-Aminobenzoylphenylharnstoffe.
DE3823318A1 (de) 1988-07-09 1990-02-22 Bayer Ag (hetero)aryloxynaphthaline mit ueber schwefel gebundenen substituenten
GB8820115D0 (en) 1988-08-24 1988-09-28 Ici Plc Insecticidal compounds
DE3905075A1 (de) 1989-02-18 1990-08-30 Hoechst Ag Benzolsulfonamide und verfahren zu ihrer herstellung
ZA913760B (en) 1990-05-24 1992-02-26 Sumitomo Chemical Co Pyridine derivatives,their production processes and their compounds for control of insect pests
GB9015658D0 (en) 1990-07-17 1990-09-05 Shell Int Research Herbicidal compounds
ATE167473T1 (de) 1990-08-20 1998-07-15 Eisai Co Ltd Sulfonamid-derivate
NZ239846A (en) 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
JP3188286B2 (ja) 1991-08-20 2001-07-16 塩野義製薬株式会社 フェニルメトキシイミノ化合物およびそれを用いる農業用殺菌剤
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
US5514696A (en) 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
JPH06199047A (ja) 1993-01-08 1994-07-19 New Oji Paper Co Ltd 感熱記録体
US5643914A (en) 1993-03-02 1997-07-01 Smithkline Beecham Corporation Pharmaceutical pyridine compounds
CA2166413A1 (en) 1993-06-30 1995-01-12 Richard James Arrowsmith Anti-atherosclerotic diaryl compounds
WO1995018097A1 (fr) 1993-12-27 1995-07-06 Eisai Co., Ltd. Derive de l'acide anthranilique
US5545669A (en) 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
US5684195A (en) 1994-07-14 1997-11-04 G. D. Searle & Co. Method of preparing sulfmonamides from sulfones
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (da) 1994-11-12 1997-12-01 Zeneca Ltd
DE19502753A1 (de) * 1995-01-23 1996-07-25 Schering Ag Neue 9H-Pyrido[3,4-b]indol-Derivate
US5780483A (en) 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
US5814646A (en) 1995-03-02 1998-09-29 Eli Lilly And Company Inhibitors of amyloid beta-protein production
US6022897A (en) 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
US5939442A (en) 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
WO1997000857A1 (fr) 1995-06-21 1997-01-09 Otsuka Kagaku Kabushiki Kaisha Derives de sulfonamides et insecticide, miticide et nematicide les contenant
US6028052A (en) 1995-09-18 2000-02-22 Ligand Pharmaceuticals Incorporated Treating NIDDM with RXR agonists
ES2205183T3 (es) 1996-02-22 2004-05-01 Tularik, Inc. Pentafluorobencenosulfonamidas y analogos.
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JPH09255656A (ja) 1996-03-28 1997-09-30 Hiroyoshi Hidaka スルフォンアミド誘導体及びこれを含有する医薬
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US6294559B1 (en) 1996-05-02 2001-09-25 Merck & Co., Inc. Antiproliferative agents associated with peroxisome proliferator activated receptors gamma1 and gamma2
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
JP3243733B2 (ja) 1996-08-07 2002-01-07 雪印乳業株式会社 新規イソキノリン誘導体
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
NZ337331A (en) 1997-02-21 2001-05-25 Bayer Ag Aryl-sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
DE69809827D1 (de) 1997-03-31 2003-01-16 Korea Res Inst Chem Tech Chinolinische Sulfid-Derivate als NMDA Rezeptor-Antagonisten und Verfahren zu ihrer Herstellung
AU7473398A (en) 1997-05-07 1998-11-27 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US5981586A (en) 1997-05-23 1999-11-09 Pershadsingh; Harrihar A. Methods for treating proliferative and inflammatory skin diseases
KR20010014183A (ko) 1997-06-27 2001-02-26 Fujisawa Pharmaceutical Co 술폰아미드 화합물 및 그의 의약 용도
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
WO1999038845A1 (en) 1998-01-29 1999-08-05 Tularik Inc. Ppar-gamma modulators
JP4327915B2 (ja) 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 スルフォンアミド誘導体
DE19837627A1 (de) 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
HN1998000027A (es) 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
US6586475B1 (en) 1998-11-20 2003-07-01 Takeda Chemical Industries, Ltd. β-amyloid protein production/secretion inhibitors
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
NZ530833A (en) * 1999-06-30 2005-08-26 Tularik Inc Compounds for the modulation of PPARgamma activity
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
US20020048610A1 (en) * 2000-01-07 2002-04-25 Cima Michael J. High-throughput formation, identification, and analysis of diverse solid-forms
TW533656B (en) 2000-04-07 2003-05-21 Mirae Corp Cooling control system of linear motor
US6653332B2 (en) 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
HUP0301482A3 (en) * 2000-06-28 2005-12-28 Japan Tobacco Inc Quinolinnyl and benzothiazolyl ppar-gamma modulators pharmaceutical compositions containing them and their use
CN1289072C (zh) 2000-12-22 2006-12-13 石原产业株式会社 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂
GB2373725A (en) 2001-03-30 2002-10-02 Novartis Ag Use of a PPAR gamma agonist in the production of a medicament for the prevention or treatment of diseases associated with IL-10 production
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
AU2005221140A1 (en) 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of PPAR (gamma) activity

Also Published As

Publication number Publication date
JP2012097090A (ja) 2012-05-24
CA2540536A1 (en) 2005-04-14
KR20060097121A (ko) 2006-09-13
MXPA06003313A (es) 2006-06-08
US20070293536A1 (en) 2007-12-20
JP5426813B2 (ja) 2014-02-26
EP1677797A2 (en) 2006-07-12
AU2004278416B2 (en) 2010-04-15
EP1677797A4 (en) 2009-03-25
EA013367B1 (ru) 2010-04-30
AU2004278416A1 (en) 2005-04-14
IL174728A (en) 2011-06-30
ES2386670T3 (es) 2012-08-24
CA2540536C (en) 2013-07-02
EP1677797B1 (en) 2012-02-22
WO2005033074A3 (en) 2005-06-16
WO2005033074A2 (en) 2005-04-14
US20050143416A1 (en) 2005-06-30
CN1886134A (zh) 2006-12-27
IS8378A (is) 2006-03-27
US8003665B2 (en) 2011-08-23
US7223761B2 (en) 2007-05-29
NO20061974L (no) 2006-07-03
BRPI0414957A (pt) 2006-11-07
KR101156277B1 (ko) 2012-07-05
IL174728A0 (en) 2006-08-20
JP2007507537A (ja) 2007-03-29
NO333002B1 (no) 2013-02-11
NZ546783A (en) 2008-11-28
EA200600701A1 (ru) 2006-10-27
ATE546142T1 (de) 2012-03-15
ZA200602669B (en) 2007-07-25

Similar Documents

Publication Publication Date Title
DK1677797T3 (da) Salte og polymorfer af en virkningsfuld antidiabetisk forbindelse
EA200700757A1 (ru) Замещённые дипиперидиновые антагонисты ccr2
CY1109529T1 (el) 2-(αμινο-υποκατεστημενες)-4-αρυλο πυραμιδινες και σχετικες ενωσεις που χρησιμευουν στην αγωγη φλεγμονωδων νοσηματων
MX2009001327A (es) Compuestos de indol.
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
DK1861100T3 (da) 3,11B-cis-dihydrotetrabenazin til behandling af en profilerativ sygdom eller en inflammation
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
CR8644A (es) Compuestos de imidazol para el tratamiento de transtornos neurodegenerativos
WO2005112921A3 (en) Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
SI1532974T1 (sl) Zmes, ki vsebuje 6-(3-(1-adamantil)-4-metoksifenil)-2-naftensko kislino, za zdravljenje dermatoloških motenj
IN2015DN00502A (da)
NI200700221A (es) Antagonistas receptor pgd2 para el tratamiento de enfermedades inflamatorias
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
DK2380584T3 (da) Immunstimulerende fremgangsmåde
CY1113314T1 (el) (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης
EA200600203A1 (ru) Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
TR201818983T4 (tr) İnflamatuvar Cilt Bozukluklarının Tedavisine Yönelik Olarak Sübstitüe Edilmiş Tetrasiklin Bileşikleri
CL2008000089A1 (es) Compuestos derivados de 2,4-pirimidinona condensada con un heterociclo, inhibidores de pde-4; composicion farmaceutica; combinacion farmaceutica; procedimiento de preparacion de los compuestos, utiles para tratar trastornos inmunes e inflamatorios.
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
WO2010040055A3 (en) Oral pharmaceutical formulations for antidiabetic compounds
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
DK1871380T3 (da) Kombineret anvendelse af prostaglandinforbindelse og protonpumpeinhibitor til behandlingen af gastrointestinale lidelser